Gamma delta T cells, a distinct immune subset comprising only 1-5% of circulating T lymphocytes, demonstrated selective cytotoxic activity against senescent cells in laboratory studies using a mouse model of idiopathic pulmonary fibrosis. These cells recognized and eliminated senescent fibroblasts through their unique T cell receptor, which operates independently of traditional antigen presentation pathways. This discovery represents a significant advance in senolytic immunotherapy, as most current approaches rely on small molecule drugs like dasatinib and quercetin that often produce systemic side effects. The gamma delta T cell mechanism offers a more precise biological targeting system that could preserve healthy tissue while clearing harmful senescent cells. Previous senolytic strategies have struggled with specificity—senolytics often affect proliferating cells or require high doses that create toxicity. The endogenous nature of this immune-mediated clearance suggests potential for therapeutic enhancement through adoptive cell transfer or stimulation of existing gamma delta populations. However, translation to human applications faces substantial hurdles, including the significant differences between mouse and human gamma delta T cell biology, the complexity of senescent cell heterogeneity in aging tissues, and the need for long-term safety data in clinical populations.